Geron Corp.’s dismantling of its stem cell research on Monday puts the pressure on companies trying to discover or develop drugs by tapping into the cells that make us what we are.
Geron may have been trying to do too much too soon, but the real issue is that human embryonic stem cell drug development clearly was costing too much money for a publicly held company (NASDAQ: GERN).
That’s a shame in many ways. After all, Menlo Park-based Geron was in stem cells before stem cells were cool from a commercial point of view — not that they are more hip now. By being one of the first to harness embryonic stem cells as a potential treatment, it blazed a trail, enduring a Food and Drug Administration hold on its trial in acute spinal cord injuries.